论文部分内容阅读
目的恶性胸腔积液是晚期恶性肿瘤的并发症,一旦出现患者生活质量将受到很大影响。本研究旨在观察康莱特联合顺铂治疗恶性胸腔积液患者的临床疗效和毒副反应。方法本组42例恶性胸腔积液,随机分成两组:两组每次胸腔注药前均胸腔内注入生理盐水加地塞米松5 mg,单药顺铂组顺铂60 mg加生理盐水30 mL胸腔内注射,联用组康莱特200 mL注入胸腔夹管48 h放开引流,尽量流尽液体后胸腔注入顺铂60 mg加生理盐水30 mL。结果单药组CR+PR是57.14%,联合组CR+PR是90.48%,两组疗效经X2检验有显著性差异P<0.05。结论康莱特与顺铂联用,治疗恶性胸腔积液副作用小、疗效高。
The purpose of malignant pleural effusion is a complication of advanced malignancies, once the quality of life of patients will be greatly affected. This study was designed to observe the clinical efficacy and side effects of Kanglaite combined with cisplatin in the treatment of patients with malignant pleural effusion. Methods The group of 42 patients with malignant pleural effusion were randomly divided into two groups: two groups were injected with saline and dexamethasone 5 mg intrathoracically each time prior to intrathoracic injection, 60 mg of cisplatin and 30 mL of thoracic cavity Injection, combined with Kanglaite 200 mL into the chest tube 48 h drainage and drainage, try to drain the liquid into the chest after injection of cisplatin 60 mg plus saline 30 mL. Results CR + PR in single drug group was 57.14%, CR + PR in combined group was 90.48%. There was significant difference between two groups (P <0.05) by X2 test. Conclusions Kanglaite combined with cisplatin, the treatment of malignant pleural effusion, side effects, high efficacy.